Cartesian Therapeutics, Inc.Cartesian Therapeutics, Inc.Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪95.31 M‬USD
−7.05USD
‪35.38 M‬USD
‪110.78 M‬USD
‪3.59 M‬
Beta (1Y)
0.18

About Cartesian Therapeutics, Inc.

CEO
Carsten Brunn
Headquarters
Gaithersburg
Employees (FY)
64
ISIN
US8162123025
FIGI
BBG001J19Q25
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides RNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Gaithersburg, MD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of RNAC is 17.51 USD — it has increased by 1.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cartesian Therapeutics, Inc. stocks are traded under the ticker RNAC.
Cartesian Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
RNAC stock is 3.63% volatile and has beta coefficient of 0.18. Check out the list of the most volatile stocks — is Cartesian Therapeutics, Inc. there?
One year price forecast for Cartesian Therapeutics, Inc. has a max estimate of 90.00 USD and a min estimate of 42.00 USD.
RNAC earnings for the last quarter are −1.35 USD per share, whereas the estimation was −2.34 USD resulting in a 42.31% surprise. The estimated earnings for the next quarter are −0.90 USD per share. See more details about Cartesian Therapeutics, Inc. earnings.
Cartesian Therapeutics, Inc. revenue for the last quarter amounts to ‪5.88 M‬ USD despite the estimated figure of ‪7.23 M‬ USD. In the next quarter revenue is expected to reach ‪2.50 M‬ USD.
Yes, you can track Cartesian Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
RNAC stock has fallen by 2.72% compared to the previous week, the month change is a 22.38% fall, over the last year Cartesian Therapeutics, Inc. has showed a 51.76% decrease.
RNAC net income for the last quarter is ‪−9.00 M‬ USD, while the quarter before that showed ‪−11.39 M‬ USD of net income which accounts for 20.94% change. Track more Cartesian Therapeutics, Inc. financial stats to get the full picture.
Today Cartesian Therapeutics, Inc. has the market capitalization of ‪95.31 M‬, it has decreased by 15.70% over the last week.
No, RNAC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RNAC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cartesian Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
RNAC reached its all-time high on Nov 28, 2016 with the price of 839.99 USD, and its all-time low was 11.67 USD and was reached on Apr 8, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 64.00 employees. See our rating of the largest employees — is Cartesian Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cartesian Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cartesian Therapeutics, Inc. stock shows the sell signal. See more of Cartesian Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cartesian Therapeutics, Inc. future price: according to them, RNAC price has a max estimate of 90.00 USD and a min estimate of 42.00 USD. Read a more detailed Cartesian Therapeutics, Inc. forecast: see what analysts think of Cartesian Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cartesian Therapeutics, Inc. EBITDA is ‪−56.54 M‬ USD, and current EBITDA margin is 14.96%. See more stats in Cartesian Therapeutics, Inc. financial statements.